Referências

  1. Food and Drug Administration. Medical devices and Clinical Trial Design for the Treatment or Improvement in the Appearance of Fungally-Infected Nails. Jan 2015. Found at: http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-meddev-gen/documents/document/ucm431312.pdf
  2. Haria M, Bryson HM. Amorolfine. A review of its pharmacological properties and therapeutic potential in the treatment of onychomycosis and other superficial fungal infections. Drugs. 1995 Jan;49(1):103-20.
  3. Polak A, Zuag M. Handbook of Experimental Pharmacology vol. 96: Chemotherapy of Fungal Diseases 1990, 504-21.
  4. Baran R, Kaoukhov A. Topical antifungal drugs for the treatment of onychomycosis: an overview of current strategies for monotherapy and combination  therapy. J Eur Acad Dermatol Venereol. 2005 Jan;19(1):21-9.
  5. Pittrof F, Gerhards J, Erni W, Klecak G. Loceryl nail lacquer - realization of a new galenical approach to onychomycosis therapy. Clin Exp Dermatol. 1992 Sep;17 Suppl 1:26-8.
  6. Faergemann J, Baran R. Epidemiology, clinical presentation and diagnosis of onychomycosis. Br J Dermatol. 2003 Sep; 149 Suppl 65:1-4.
  7. Effendy I, Lecha M, Feuilhade de Chauvin M, Di Chiacchio N, Baran R; European  Onychomycosis Observatory. Epidemiology and clinical classification of onychomycosis. J Eur Acad Dermatol Venereol. 2005 Sep; 19 Suppl 1:8-12.
  8. Monod M. Secreted proteases from dermatophytes. Mycopathologia. 2008 Nov; 166(5):285-94.
  9. Szepietowski JC, Reich A, Garlowska E, Kulig M, Baran  E, for the Onychomycosis Epidemiology Study Group. Factors influencing coexistence of toenail onychomycosis with tinea pedis and other dermatomycoses. Arch Dermatol. 2006; Oct; 142:1279-84.
  10. Elewski BE. Onychomycosis: pathogenesis, diagnosis, and management. Clin Microbiol Rev. 1998; 11(3):415-29.
  11. Hay RJ, Baron R. Onychomycosis: a proposed revision of the clinical classification. J Am Acad Dermatol. 2011 Dec; 65(6):1219-27
  12. Tosti A, Arenas-Guzmán R. Patients at risk of onychomycosis-risk factor identification and active prevention. J Eur Acad Dermatol Venereol. 2005 Sept;19(S1):13-6.
  13. Baran R, Hay RJ, Garduno JI. Review of antifungal therapy and the severity index for assessing onychomycosis: part I. J Dermatolog Treat. 2008 Jan; 19(2):72-81.
  14. Polak A. Amorolfine: A review of its mode of action and in vitro and in vivo antifungal activity. Suppl to J Am Acad Dermatol South-East Asia. 1993 July:11-18.
  15. Loceryl Nail Lacquer 5% - (eMC). Galderma.
  16. Gupta AK, Daigle D, Foley KA. Topical therapy for toenail onychomycosis: an evidence-based review. Am J Clin Dermatol. 2014 Dec; 15(6):489-502.
  17. Polak A, Jäckel A, Noack A, Kappe R.Agar sublimation test for the in vitro determination of the antifungal activity of morpholine derivatives. Mycoses. 2004 Jun; 47(5-6):184-92.
  18. Ghannoum M, Sevin K,  Sarkany M. Amorolfine 5% nail lacquer exhibits potent antifungal activity compared to three acid-based devices indicated for the treatment of onychomycosis: an in vitro nail penetration assay. Dermatology and Therapy. 2015 in press.
  19. Sidou F.  A randomized comparison of nail surface remanence of three nail lacquers, containing amorolfine 5%, ciclopirox 8% or tioconazole 28%, in healthy volunteers. Int J Tissue React. 2004; 26(1-2):17-24.
  20. Sigurgeirsson B, Olafsson JH, Steinsson JT, Kerrouche N, Sidou F. Efficacy of amorolfine nail lacquer for the prophylaxis of onychomycosis over 3 years. J Eur Acad Dermatol Venereol. 2010; 24:910-15.
  21. Yaemsiri S, Hou N, Slining MM, He K. Growth rate of human fingernails and toenails in healthy American young adults. J Eur Acad Dermatol Venereol. 2010; 24(4):420-3.

©2015  Galderma